SCHEMBL15076187

SCHEMBL15076187

CCC(CC)COc1ccc(Br)cc1COS(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 1/20 0.39
▸ RAB9A P51151 5/20 0.37
▸ SMN1; SMN2 Q16637 5/20 0.37
▸ LMNA P02545 4/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ CCR5 P51681 6/20 0.36
▸ NPC1 O15118 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ HTR7 P34969 1/20 0.34
▸ HTR6 P50406 1/20 0.34
▸ THRA P10827 1/20 0.34
▸ THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15054408 0.86 CCR5 (0.40) PTGDR2RAB9ASMN1; SMN2LMNAKMT2A
SCHEMBL15052213 0.84 PTGER1 (0.39) ALDH1A1KDM4ETSHRMAPT
SCHEMBL15051963 0.79 PTGDR2 (0.56) PTGDR2RAB9ASMN1; SMN2LMNAKMT2A
SCHEMBL15413756 0.79 LMNA (0.49) SMN1; SMN2LMNAKMT2AALDH1A1KDM4E
SCHEMBL20628804 0.78 RAB9A (0.39) PTGDR2RAB9ASMN1; SMN2LMNAKMT2A
SCHEMBL14709471 0.75 SMN1; SMN2 (0.36) RAB9ASMN1; SMN2LMNAKMT2ACCR5
SCHEMBL20629012 0.72 AAK1 (0.45) RAB9ASMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL15058239 0.72 KDM4E (0.38) PTGDR2RAB9ASMN1; SMN2LMNAKMT2A
SCHEMBL2521711 0.71 HTR2A (0.38) SMN1; SMN2LMNAKMT2ACCR5ALDH1A1
SCHEMBL18498917 0.71 L3MBTL1 (0.36) SMN1; SMN2LMNAALDH1A1HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210221810-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2021-07-22 — — US disclosed
US-20210221810-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2021-07-22 — — US disclosed
US-10988474-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2021-04-27 — — US disclosed
US-10988474-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2021-04-27 — — US disclosed
EP-3424904-B1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2020-12-02 — — EP disclosed
EP-3424904-B1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2020-12-02 — — EP disclosed
US-20200216440-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2020-07-09 — — US disclosed
US-20200216440-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2020-07-09 — — US disclosed
US-10392382-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2019-08-27 — — US disclosed
US-10392382-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2019-08-27 — — US disclosed
US-20170137423-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2017-05-18 — — US disclosed
US-20170137423-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2017-05-18 — — US disclosed
US-20170137423-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2017-05-18 — — US disclosed
US-9567328-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2017-02-14 — — US disclosed
US-9567328-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2017-02-14 — — US disclosed
US-9567328-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2017-02-14 — — US disclosed
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-07-18 — — US disclosed
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-07-18 — — US disclosed
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-07-18 — — US disclosed
WO-2013096496-A2 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216440-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 PTGDR2 10/4885RAB9A 4208/4885SMN1; SMN2 3991/4885
US-20210221810-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 PTGDR2 10/4885RAB9A 4208/4885SMN1; SMN2 3991/4885
US-10392382-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response PTGER1, PTGER4, PTGER2 PTGDR2 10/4885RAB9A 4208/4885SMN1; SMN2 3991/4885
US-10988474-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response PTGER1, PTGER4, PTGER2 PTGDR2 10/4885RAB9A 4208/4885SMN1; SMN2 3991/4885
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 PTGDR2 10/4885RAB9A 4208/4885SMN1; SMN2 3991/4885
US-20170137423-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 PTGDR2 10/4885RAB9A 4208/4885SMN1; SMN2 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback